Provectus to present on preclinical PV-10 vaccine data at SITC Meeting

Provectus announced that preclinical data from ongoing research on the potential use of investigational cancer immunotherapy PV-10 as an adjuvant in vaccines to help them work better was the subject of a poster presentation at the Society for Immunotherapy of Cancer 2023 annual meeting, which was held in San Diego, CA from November 1-5. This research has been led by Aru Narendran, MD, PhD and his lab team from the Cumming School of Medicine at the University of Calgary in Alberta, Canada. Dr. Narendran and his colleagues previously discovered that PV-10 activated stimulator of interferon genes, demonstrating its potential as a vaccine adjuvant in PV-10-mediated systemic anti-tumor immune responses. See Thakur et al., American Association for Cancer Research 2020 Virtual Annual Meeting II. In its SITC work, the Narendran lab showed that PV-10 treatment induced STING activation, upregulated cytokines and chemokines, and increased IFN-gamma secretion by CD8+ T-cells. Dr. Narendran and his colleagues demonstrated PV-10’s ability to function as an effective adjuvant to enhance T-cell responses and concluded that PV-10’s unique modulation of the STING pathway was a potential mechanism of this activity.